Figure 1. Effects of TAK228 on cell proliferation in vitro.

(A) Eight triple negative breast cancer cell lines were treated for 48 hours with DMSO or varying doses of TAK228 ranging from 10 nM to 1000 nM, a physiologically achievable dose. Cells were lysed and blotted with the indicated antibodies. (B) The same panel of cell lines in (A) were treated with TAK228 at 6 concentrations based on a five-fold dilution series (range 0 to 10 μM). Cell growth was measured after 72 hours of treatment using the sulforhodamine B assay, and half-maximal inhibitory concentration (IC₅₀) was then calculated using isobologram curves. Sensitivity was defined as IC₅₀ < 80 nM. (C) The same panel of cell lines (A) were lysed and blotted with indicated antibodies. PTEN and PIK3CA mutation statuses demonstrated with black indicating mutation and white indicating wildtype.